AJAC  Vol.5 No.14 , October 2014
Development and Validation of RP-UPLC Method for the Determination of Iloperidone, Its Related Compounds and Degradation Products in Bulk and Dosage Form
Abstract: A rapid, specific, sensitive, and precise reverse-phase UPLC method developed for the quantitative determination of an atypical antipsychotic drug Iloperidone and its eight potential impurities in drug substances and drug products is described in this report. Chromatographic separation was achieved on a Waters Acquity UPLC® HSS C18 (2.1 mm × 100 mm, 1.8 micron) column thermostated at 35°C with a short runtime of 10 min. Quantification is achieved with photodiode array detection at 225 nm over the concentration range of 0.03 - 0.15 μg/mL. Forced degradation study was carried out under acidic, alkaline, oxidative, photolytic and thermal conditions to demonstrate the stability-indicating capability of the developed UPLC method. Comparison of system performance with conventional high-performance liquid chromatography is made with respect to analysis time, efficiency, and sensitivity. The method is validated according to the ICH guidelines and is applied successfully for the determination of Iloperidone in tablets.
Cite this paper: Landge, S. , Jadhav, S. , Vishwambar, S. , Solanki, P. , Bembalkar, S. and Mathad, V. (2014) Development and Validation of RP-UPLC Method for the Determination of Iloperidone, Its Related Compounds and Degradation Products in Bulk and Dosage Form. American Journal of Analytical Chemistry, 5, 969-981. doi: 10.4236/ajac.2014.514104.

[1]   Wren, S.A.C. and Tchelitcheff, P. (2006) Use of Ultra-Performance Liquid Chromatography in Pharmaceutical Development. Journal of Chromatography A, 1119, 140-146.

[2]   Snyder, L.R., Kirkland, J.J. and Dolan, J.W. (1997) Introduction to Modern Liquid Chromatography.

[3]   Weiden, P.J. (2012) Iloperidone for the Treatment of Schizophrenia: An Updated Clinical Review. Clinical Schizophrenia & Related Psychoses, 34-44.

[4]   Center for Drug Evaluation and Research (2009) NDA Approval Letter. Application Number 22-192.

[5]   Bishop, J.R. and Bishop, D.L. (2010) Iloperidone for the Treatment of Schizophrenia. Drugs, 46, 567-579.

[6]   Arif, S.A. and Mitchell, M.M. (2011) Iloperidone: A New Drug for the Treatment of Schizophrenia. American Journal of Health-System Pharmacy, 68, 301-308.

[7]   Nakano, M., Kitano, S., Nanri, M. and Kiniwa, M. (2011) Iloperidone, a Unique Histamine H2-Receptor Antagonist, Inhibits Distention-Induced Gastric Acid Secretion through an H2 Receptor-Independent Mechanism. European Journal of Pharmacology, 658, 236-241.

[8]   Dewan, B. and Philipose, N. (2011) Iloperidone 10 mg versus Rabeprazole 20 mg in the Treatment of Patients with Heartburn-Dominant Uninvestigated Dyspepsia: A Randomized, Multicentric Trial. Gastroenterology Research and Practice, 2011, Article ID: 640685.

[9]   Shimatani, T., Inoue, M., Kuroiwa, T., Xu, J., Nakamura, M., Tazuma, S., Ikawa, K. and Morikawa, N. (2006) Iloperidone, a Newly Developed Antiulcer Drug, Elevates Postprandial Intragastric pH and Increases Plasma Calcitonin Gene-Related Peptide and Somatostatin Concentrations in Humans: Comparisons with Famotidine. Digestive Diseases and Sciences, 51, 114-120.

[10]   Snyder, L.R., Kirkland, J.J. and Glajch, J.L. (1997) Practical HPLC Method Development. 2nd Edition.

[11]   Wu, L.L., Zhang, Z.J., Tian, Y., Li, W., Xu, F.G., Chen, Y. and Wei, H.L. (2005) Determination of Lafutidine in Human Plasma by High-Performance Liquid Chromatography-Electrospray Ionization Mass Spectrometry: Application to a Bioequivalence Study. Journal of Mass Spectrometry, 40, 1637-1643.

[12]   Chen, W.D., Liang, Y., Li, H., Xiong, Y., Liu, X., Wang, G.J. and Xie, L. (2006) Simple, Sensitive and Rapid LC-ESI-MS Method for the Quantitation of Iloperidone in Human Plasma-Application to Pharmacokinetic Studies. Journal of Pharmaceutical and Biomedical Analysis, 41, 256-260.

[13]   Mutlib, A.E., Strupczewski, J.T. and Chesson, S.M. (1995) Application of Hyphenated LC/NMR and LC/MS Techniques in Rapid Identification of in Vitro and in Vivo Metabolites of Iloperidone. Drug Metabolism and Disposition, 23, 951-964.

[14]   Mandpe, L.P. and Pokharkar, V.B. (2011) Stress Degradation Studies on Iloperidone and Development of a Stability Indicating HPLC Method for Bulk Drug and Pharmaceutical Dosage Form. Der Chemica Sinica, 2, 230-239.

[15]   Sumithra, M., Sundaram, P.S. and Srinivasulu, K. (2011) Analytical Method Development and Validation of Iloperidone in Tablet Dosage form by RP-HPLC. International Journal of ChemTech Research, 3, 1403-1407.

[16]   Chhalotiya, U.K., Bhatt, K.K., Shah, D.A. and Patel, J.R. (2012) Liquid Chromatographic Method for the Quantification of Antipsychotic Agent Iloperidone in Pharmaceutical Formulation. ISRN (International Scholarly Research Network) Analytical Chemistry, 2012, Article ID: 963276.

[17]   Manjula Devi, A.S. and Ravi, T.K. (2012) Validation of UV Spectrophotometric and HPLC Methods for Quantitative Determination of Iloperidone in Pharmaceutical Dosage Form. International Journal of PharmTech Research, 4, 576-581.

[18]   Saravanan, G., Yunoos, M. and Shahanaz, S.K. (2013) A Validated Reverse Phase High Performance Liquid Chromatographic Assay Method for the Estimation of Iloperidone in Bulk and Commercial Tablet Dosage Form. Journal of Chemical and Pharmaceutical Research, 5, 506-511.

[19]   Solanki, P.V., Uppelli, S.B., Pandit, B.S. and Mathad, V.T. (2014) Improved and Efficient Process for the Production of Highly Pure Iloperidone: A Psychotropic Agent. Organic Process Research and Development, 18, 342-348.

[20]   The United States Pharmacopeia (2009) Validation of Compendial Methods. 36th Edition (USP 36), Rockville.

[21]   International Federation of Pharmaceutical Manufactures & Associations (IFPMA) (1996) Validation of Analytical Procedure. International Conference on Harmonization (ICH), Methodology Q2(R1), Geneva.

[22]   Ruan, J., Tattersall, P., Lozano, R. and Shah, P. (2006) The Role of Forced Degradation Studies in Stability Indicating HPLC Method Development. American Pharmaceutical Review, 9, 46-53.

[23]   Bakshi, M. and Singh, S. (2002) Development of Validated Stability-Indicating Assay Methods—Critical Review. Journal of Pharmaceutical and Biomedical Analysis, 28, 1011-1040.

[24]   Carstensen, J.T. and Rhodes, C.T. (2000) Drug Stability Principles and Practices. 3rd Edition, Marcel Dekker, New York.